Xebra Brands Receives Its First-Ever Federal Authorization for Legal CBD Launch in Mexico

Vancouver, British Columbia--(Newsfile Corp. - February 27, 2024) - Xebra Brands Ltd. (CSE: XBRA) (OTCQB: XBRAD) (FSE: 9YC0) ("Xebra" or the "Company"), a cannabis company, announces that it has been granted its first product authorization for the importation, launch and sale of its 250mg Tangerine Flavor CBD Tincture in Mexico. This first Federal Authorization marks a significant milestone for Mexico and Xebra Brands and underscores Xebra's commitment to expanding access to high-quality CBD products in Mexico.

The authorization granted to Elements Bioscience S.A. de C.V, a fully owned subsidiary of Xebra Brands Ltd, by Mexican regulatory authorities (COFEPRIS) is a testament to the company's dedication to compliance, quality, and innovation in the CBD industry. Xebra Brands has worked diligently to ensure that its Tangerine Flavour CBD Tincture meets the highest standards of safety, purity, and efficacy, providing consumers in Mexico with a trusted and reliable CBD option.

"We are thrilled to receive our first-ever Federal authorization for the launch of our Tangerine Flavour CBD Tincture in Mexico," said Rodrigo Gallardo, Interim CEO of Xebra Brands. "This milestone represents a significant step forward in our mission to make high-quality legal CBD products accessible to consumers. We are grateful for the support of regulatory authorities in Mexico and look forward to bringing our premium CBD tincture to customers across the country."

Xebra Brands' 250mg Tangerine Flavour CBD Tincture is crafted with care using only the finest ingredients, including premium CBD extract and premium tangerine flavouring. Each batch of tincture undergoes rigorous testing by third-party laboratories to ensure potency, purity, and consistency, providing consumers with peace of mind and confidence in their CBD experience.

The launch of Xebra Brands' Tangerine Flavour CBD Tincture in Mexico represents a significant opportunity for consumers seeking natural wellness solutions. CBD has gained popularity worldwide for its potential therapeutic benefits, including stress relief, relaxation, and overall well-being.

Xebra Brands remains committed to leading the way in the legal Mexican CBD industry, delivering innovative products that meet the evolving needs of consumers. With the authorization for its Tangerine Flavour CBD Tincture in Mexico, Xebra Brands adds its first import authorization that will run in parallel to its domestically produced Mexican products and is poised to make a positive impact on the lives of individuals seeking natural alternatives for health and wellness.

ABOUT XEBRA

Xebra is an International cannabis company focused on the development and sale of cannabis and CBD products in Mexico. Xebra is an absolute first mover in the Mexican cannabis sector, with the first ever granted authorization to a corporation by the COFEPRIS.

ON BEHALF OF THE BOARD:

Rodrigo Gallardo
Interim CEO

For more information contact:
1(888) XEBRA 88
ir@xebrabrands.com

Certain information contained in this press release constitutes forward-looking statements under applicable securities laws. Any statements that are not statements of historical fact may be deemed to be forward-looking statements, these include, without limitation, statements regarding Xebra Brands Ltd.'s expectations in respect of its ability to successfully execute its business plan or business model; its ability to enter into and execute partnerships or joint venture opportunities on acceptable terms; statements regarding expected benefits of partnerships and supply agreements, its ability to provide economic, environmental, social, or any benefits of any type in the communities it operates in or may operate it in the future; its ability to be a first mover in a country, or to obtain or retain government licenses, permits or authorizations in general, or specifically in Mexico, Canada, or elsewhere, including cannabis authorizations from the Mexican Health Regulatory Agency (COFEPRIS); its ability to satisfy the conditions of authorizations granted by COFEPRIS; its ability to successfully apply for, obtain and retain trademarks and other intellectual property in any jurisdiction; its ability to be cost competitive; its ability to commercialize, cultivate, grow, or process hemp or cannabis in Mexico, Canada, or elsewhere and related plans and timing; its ability to manufacture, commercialize or sell cannabis-infused beverages, wellness products, or other products in Mexico, Canada, or elsewhere, and its related plans and claims, including market interest and availability; its ability to create wellness products that have a therapeutic effect or benefit; plans for future growth and the direction of the business; plans to increase product volumes, the capacity of existing facilities, supplies from third party growers and contractors; expected growth of the cannabis industry generally; management's expectations, beliefs and assumptions in general, including manufacturing costs, production activity and market potential in Mexico or any jurisdiction; events or developments that Xebra expects to take place in the future; general economic conditions; and other risk factors described in the MD&A of the Company for the period ended November 30, 2023. All statements, other than statements of historical facts, are forward-looking information and statements. The words "aim", "believe", "expect", "anticipate", "contemplate", "target", "intends", "continue", "plans", "budget", "estimate", "may", "will", and similar expressions identify forward-looking information and statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Xebra as of the dates of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Known and unknown factors could cause actual results to differ materially from those projected in the forward-looking statements. Such factors include, but are not limited to, the inability of Xebra to retain the authorizations granted by COFEPRIS, the inability to successfully complete financings on terms acceptable to Xebra or at all, the inability to generate sufficient revenues or to raise sufficient funds to carry out its business plan; changes in government legislation, taxation, controls, regulations and political or economic developments in various countries; risks associated with agriculture and cultivation activities generally, including inclement weather, access to supply of seeds, poor crop yields, and spoilage; compliance with import and export laws of various countries; significant fluctuations in cannabis prices and transportation costs; the risk of obtaining necessary licenses and permits; inability to identify, negotiate and complete potential acquisitions, dispositions or joint ventures for any reason; the ability to retain key employees; dependence on third parties for services and supplies; non-performance by contractual counter-parties; general economic conditions; the continued growth in global demand for cannabis products and the continued increase in jurisdictions legalizing cannabis; and the timely receipt of regulatory approvals for license applications on terms satisfactory to Xebra. In addition, there is no assurance Xebra will: be a low-cost producer or exporter; obtain a dominant market position in any jurisdiction; have products that will be unique. The foregoing list is not exhaustive and Xebra undertakes no obligation to update or revise any of the foregoing except as required by law. Many of these uncertainties and contingencies could affect Xebra's actual performance and cause its actual performance to differ materially from what has been expressed or implied in any forward-looking statements made by, or on behalf of, Xebra. Readers are cautioned that forward-looking statements are not guarantees of future performance and readers should not place undue reliance on such forward-looking statements. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those set out in such statements.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/199459